Getting to the Heart of the Matter: Biomarkers for the Assessment of Trastuzumab-Induced Cardiac Dysfunction

By Deepa Rangachari

This podcast focuses on the use of trastuzumab in adjuvant therapy for early stage, Her2-positive breast cancer and ongoing efforts to identify predictive and prognostic biomarkers for the assessment of treatment-related cardiac toxicity.

Related Article: Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy